论文部分内容阅读
目的:观察单药紫杉醇脂质体周剂量治疗老年晚期非小细胞肺癌(NSCLC)的临床疗效和毒副反应。方法:紫杉醇脂质体60mg/m2,静脉滴入,d1,每周1次,连用6周,休息2周为1个周期。结果:全组33例患者均可评价疗效,其中CR2例(6.06%),PR6例(18.18%),SD19例(57.57%),PD6例(18.18%),总有效率(CR+PR)为24.24%(8/33),中位生存期7.1个月,1年生存率30.3%(10/33)。过敏反应、肌痛/关节痛及周围神经毒性仅3.03%(1/33)。结论:单药紫杉醇脂质体治疗老年晚期NSCLC具有较好的疗效和耐受性,毒副反应轻,有推广价值。
Objective: To observe the clinical efficacy and side effects of single-dose paclitaxel liposomes in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC). Methods: paclitaxel liposome 60mg / m2, intravenous infusion, d1, once a week, once every 6 weeks, rest 2 weeks for a cycle. Results: All the 33 patients could evaluate the curative effect. CR2 cases (6.06%), PR6 cases (18.18%), SD19 cases (57.57%) and PD6 cases (18.18%), the total effective rate 24.24% (8/33). The median survival time was 7.1 months. The 1-year survival rate was 30.3% (10/33). Allergic reactions, myalgia / arthralgia and peripheral neurotoxicity were only 3.03% (1/33). Conclusion: The single-agent paclitaxel liposomes have good curative effect and tolerability in elderly patients with advanced NSCLC.